EU-NCL will provide a comprehensive set of characterisation tests
European Nanomedicine Characterization Laboratory (EUNCL) provides a comprehensive set of characterization parameters (physical, chemical, in-vitro and in-vivo biological properties) allowing researchers in academia, industry and government to translate their nanoproducts towards clinical evaluation more rapidly and for lower cost. EUNCL aims to subsequently ease the translation through preclinical evaluation to safe clinical products, reduce the development risks and eliminate Med-NPs unfit for clinical use at an early stage.
The EUNCL will offer a comprehensive portfolio of assays (Assay Cascade) that will allow the full characterization of the nanoparticles’ physico-chemicals attributes, their in vitro biological properties, and their in vivo compatibility using animal models in a constant quality controlled environment.
After quality pre-check and in adequacy with the nanoparticle type and expected objective, the EU-NCL will provide an appropriate set of assays through a dedicated characterization plan.
The time required to characterize a nanomaterial from reception through the in vivo phase is anticipated to be 1 year. Proposed nanotechnology materials and strategies submitted to the EUNCL will be evaluated according to their projected impact on clinical cancer applications and/or furthering nanotechnology's compatibility with biological systems. If a nanotechnology strategy/material is selected for characterization, the EUNCL's services will be provided at no cost to the submitting investigator.
The primary outcome of the EUNCL assay cascade is the collection of data on the nanoparticles’ characteristics and their interaction and compatibility with biological systems (in vitro and in vivo). These data will be provided to the sponsor/client through a report to support a CTA application and subsequent clinical trials.
European Nanomedicine Characterisation Laboratory (EU-NCL)